首页> 外文期刊>Journal of refractive surgery >Laser in situ keratomileusis for compound myopic astigmatism using the Meditec MEL 70 G-Scan excimer laser.
【24h】

Laser in situ keratomileusis for compound myopic astigmatism using the Meditec MEL 70 G-Scan excimer laser.

机译:使用Meditec MEL 70 G-Scan准分子激光原位角膜磨镶术治疗复合性近视散光。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To determine the safety, efficacy, predictability, and stability of laser in situ keratomileusis (LASIK) in treating patients with myopic astigmatism using the Meditec MEL 70 G-Scan excimer laser. METHODS: Seventy-four eyes of 42 patients with myopia ranging from -4.50 to -9.88 D and astigmatism ranging from 0.50 to 4.00 D who underwent LASIK with the Meditec MEL 70 G-Scan excimer laser and the Summit Krumeich-Barraquer microkeratome were studied. Patients were followed for 1 year. RESULTS: Mean baseline spherical equivalent refraction was -7.12 +/- 1.70 D and cylinder was 1.62 +/- 1.72 D. At 12 months, mean postoperative spherical equivalent refraction was -0.49 +/- 0.57 D and mean refractive cylinder was 0.59 +/- 0.32 D. Mean change in spherical equivalent refraction between 1 and 12 months after surgery was -0.09 +/- 0.31 D, toward myopia. At baseline, no eyes had best spectacle-corrected visual acuity (BSCVA) of 20/20 or better, and 65% had 20/40 or better. At 12 months after surgery, 10% of eyes had BSCVA of 20/20 or better and 88% of eyes had 20/40 or better. The unusually low postoperative BSCVA results were thought to be due to amblyopia or existence of a higher percentage of some optical aberrations in this group of eyes. Mean uncorrected visual acuity was -1.38 +/- 0.42 LogMAR units (20/400) at baseline and -0.29 +/- 0.25 LogMAR units (20/40) at the 12-month postoperative examination. No eyes lost two or more lines of spectacle-corrected visual acuity. No vision threatening complications were observed. CONCLUSIONS: LASIK with the Meditec MEL 70 G-Scan excimer laser appeared to be safe, effective, reasonably predictable, and stable for correction of myopic astigmatism with a spherical component between -4.25 and -8.25 D and a cylindrical component between 0.50 and 4.00 D. However, astigmatism was slightly undercorrected with the algorithm used.
机译:目的:确定使用Meditec MEL 70 G-Scan准分子激光治疗原位角膜磨镶术(LASIK)在治疗近视散光患者中的安全性,有效性,可预测性和稳定性。方法:研究了42例近视患者,其范围为-4.50至-9.88 D,散光度范围为0.50至4.00 D,其中74眼是通过Meditec MEL 70 G-Scan准分子激光和Summit Krumeich-Barraquer微角膜刀进行的LASIK手术。随访患者1年。结果:平均基线球面等效屈光度为-7.12 +/- 1.70 D,圆柱度为1.62 +/- 1.72D。在12个月时,术后平均球面等效屈光度为-0.49 +/- 0.57 D,平均屈光度为0.59 + / -0.32D。手术后1到12个月之间,近视眼的平均球镜屈光度的平均变化为-0.09 +/- 0.31D。在基线时,没有眼睛具有20/20或更高的最佳眼镜矫正视力(BSCVA),而65%的眼睛具有20/40或更高的眼镜矫正视力。术后12个月,有10%的眼睛的BSCVA为20/20或更高,有88%的眼睛的BSCVA为20/40或更高。术后BSCVA异常低的结果被认为是由于弱视或在这组眼睛中存在较高百分比的某些光学像差。术后12个月平均未矫正视力在基线时为-1.38 +/- 0.42 LogMAR单位(20/400),在术后12个月检查时为-0.29 +/- 0.25 LogMAR单位(20/40)。没有眼睛失去两行或两行以上的眼镜矫正视力。没有观察到威胁视力的并发症。结论:使用Meditec MEL 70 G-Scan准分子激光进行的LASIK矫正近视散光似乎是安全,有效,合理地可预测且稳定的,其中球面分量在-4.25至-8.25 D之间,而柱面分量在0.50至4.00 D之间但是,使用的算法对散光的校正略有不足。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号